File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Article: Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial

TitlePembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial
Authors
Issue Date2020
PublisherS. Karger AG. The Journal's web site is located at http://content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=255487
Citation
Liver Cancer (Forthcoming) How to Cite?
Persistent Identifierhttp://hdl.handle.net/10722/289771
ISSN
2023 Impact Factor: 11.6
2023 SCImago Journal Rankings: 3.599

 

DC FieldValueLanguage
dc.contributor.authorKudo, M-
dc.contributor.authorLim, HY-
dc.contributor.authorCheng, AL-
dc.contributor.authorChao, Y-
dc.contributor.authorYau, TCC-
dc.contributor.authorOgasawara, S-
dc.contributor.authorKurosaki, M-
dc.contributor.authorMorimoto, N-
dc.contributor.authorOhkawa, K-
dc.contributor.authorYamashita, T-
dc.contributor.authorLee, KH-
dc.contributor.authorChen, E-
dc.contributor.authorSiegel, AB-
dc.contributor.authorRyoo, BY-
dc.date.accessioned2020-10-22T08:17:14Z-
dc.date.available2020-10-22T08:17:14Z-
dc.date.issued2020-
dc.identifier.citationLiver Cancer (Forthcoming)-
dc.identifier.issn2235-1795-
dc.identifier.urihttp://hdl.handle.net/10722/289771-
dc.languageeng-
dc.publisherS. Karger AG. The Journal's web site is located at http://content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=255487-
dc.relation.ispartofLiver Cancer-
dc.rightsLiver Cancer. Copyright © S. Karger AG.-
dc.rightsThis is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g., Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/?doi=[insert DOI number]. OR This is the un-reviewed and unedited manuscript version of the following article: [insert full citation, e.g., Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/?doi=[insert DOI number].-
dc.titlePembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial-
dc.typeArticle-
dc.identifier.emailYau, TCC: tyaucc@hku.hk-
dc.identifier.authorityYau, TCC=rp01466-
dc.identifier.hkuros316118-
dc.publisher.placeSwitzerland-
dc.identifier.issnl1664-5553-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats